Fentanyl transdermal matrix patch (Durotep® MT patch; Durogesic® DTrans®; Durogesic® SMAT): In adults with cancer-related pain

Drugs

Volumn 68, Issue 12, 2008, Pages 1711-1721

  Hoy, Sheridan M ^a,b   Keating, Gillian M ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Adis Drug Profiles; Cancer pain; Fentanyl, general; Transdermal

Indexed keywords

AMIODARONE; BUPRENORPHINE; CLARITHROMYCIN; CYTOCHROME P450 3A4; DELTA OPIATE RECEPTOR; DILTIAZEM; DUROGESIC DTRANS; DUROGESIC SMAT; DUROTEP MT PATCH; ERYTHROMYCIN; FENTANYL; ITRACONAZOLE; KAPPA OPIATE RECEPTOR; KETOCONAZOLE; MORPHINE; MU OPIATE RECEPTOR; NALTREXONE; NELFINAVIR; NONSTEROID ANTIINFLAMMATORY AGENT; OXYCODONE; RITONAVIR; VERAPAMIL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANALGESIA; ANTINOCICEPTION; APPLICATION SITE ERYTHEMA; APPLICATION SITE IRRITATION; APPLICATION SITE PRURITUS; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BIOEQUIVALENCE; CANCER PAIN; CLINICAL TRIAL; CONSTIPATION; DAYTIME SOMNOLENCE; DIARRHEA; DROWSINESS; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PREFERENCE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; LIVER FUNCTION; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MICTURITION DISORDER; NAUSEA; PRURITUS; RASH; RESPIRATION DEPRESSION; RESPIRATORY FAILURE; REVIEW; SIDE EFFECT; SKIN ALLERGY; SOMNOLENCE; SWEATING; THROMBOCYTE COUNT; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSDERMAL PATCH; UREA NITROGEN BLOOD LEVEL; VOMITING; XEROSTOMIA;

ADMINISTRATION, CUTANEOUS; ADULT; ANALGESICS, OPIOID; AREA UNDER CURVE; CLINICAL TRIALS, PHASE II AS TOPIC; CONSTIPATION; DIARRHEA; DISORDERS OF EXCESSIVE SOMNOLENCE; FENTANYL; HALF-LIFE; HUMANS; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; NAUSEA; NEOPLASMS; PAIN; PILOT PROJECTS; RECEPTORS, OPIOID, MU; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME; VOMITING;

EID: 49149123466     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868120-00008     Document Type: Review

References (28)

1. Davis MP, Lasheen W, Gamier P. Practical guide to opioids and their complications in managing cancer pain: what oncologists need to know. Oncology (Williston Park) 2007 Sep; 21 (10): 1229-38
2. Portenoy RK, Lesage P. Management of cancer pain. Lancet 1999 May 15; 353 (9165): 1695-700
3. Schmid-Grendelmeier P, Pokorny R, Gasser UE, et al. A comparison of the skin irritation potential of transdermal fentanyl versus transdermal buprenorphine in middle-aged to elderly healthy volunteers. Curr Med Res Opin 2006 Mar; 22 (3): 501-9
4. Muijsers RBR, Wagstaff AJ. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs 2001; 61 (15): 2289-307
5. Sathyan G, Guo C, Sivakumar K, et al. Evaluation of the bioequivalence of two transdermal fentanyl systems following single and repeat applications. Curr Med Res Opin 2005 Dec; 21 (12): 1961-8
6. Davis MP. Management of cancer pain: focus on new opioid analgesic formulations. Am J Cancer 2006; 5 (3): 171-82
7. Janssen L.P. Important drug warning [online]. Available from URL: http://www.fda.gov/medwatch/safety/2005/duragesic_ddl.pdf [Accessed 2008 Mar 10]
8. Durotep® MT Patch (transdermal fentanyl matrix patch) 2.1mg/4.2mg/8.4mg/12.6mg/16.8mg: Japanese prescribing information. Tokyo: Janssen Pharmaceutical K.K, 2008
9. Janssen-Cilag. Durogesic® DTrans® 12/25/50/75/100 transdermal patch: summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2008 Jan 31]
10. Jeal W, Benfield P. Transdermal fentanyl: a review of its pharmacological properties and therapeutic efficacy in pain control. Drugs 1997 Jan; 53 (1): 109-38
11. Martin WR, Eades CG, Thompson JA, et al. The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 1976 Jun; 197 (3): 517-32
12. Chen Y, Mestek A, Liu J, et al. Molecular cloning and functional expression of a mu-opioid receptor from rat brain. Mol Pharmacol 1993 Jul; 44 (1): 8-12
13. Nicholson B. Responsible prescribing of opioids for the management of chronic pain. Drugs 2003; 63 (1): 17-32
14. Moskowitz AS, Goodman RR. Autoradiographic analysis of mu1, mu2, and delta opioid binding in the central nervous system of C57BL/6BY and CXBK (opioid receptor-deficient) mice. Brain Res 1985 Dec 23; 360 (1-2): 108-16
15. Suzuki T, Funada M, Narita M, et al. Morphine-induced place preference in the CXBK mouse: characteristics of mu opioid receptor subtypes. Brain Res 1993 Jan 29; 602 (1): 45-52
16. Gutstein HB, Akil H. Opioid analgesics. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York: McGraw-Hill, 2006: 547-90
17. Sweetman SC. Martindale: the complete drug reference. 35th ed. London: Pharmaceutical Press, 2007
18. Maguire P, Tsai N, Kamal J, et al. Pharmacological profiles of fentanyl analogs at mu, delta and kappa opiate receptors. Eur J Pharmacol 1992 Mar 24; 213 (2): 219-25
19. Narita M, Imai S, Itou Y, et al. Possible involvement of mu1-opioid receptors in the fentanyl- or morphine-induced antinociception at supraspinal and spinal sites. Life Sci 2002 Apr 5; 70 (20): 2341-54
20. Imai S, Narita M, Itou Y, et al. Possible involvement of morphine-insensitive mu1-opioid receptors in the fentanyl-induced antinociception [abstract no. Mon26]. 31st Meeting of the International Narcotics Research Conference; 2000 Jul 15-20; Seattle (WA)
21. Donner B, Zenz M. Transdermal fentanyl: a new step on the therapeutic ladder. Anticancer Drugs 1995 Apr; 6 Suppl. 3: 39-43
22. Herz A, Albus K, Metys J, et al. On the central sites for the antinociceptive action of morphine and fentanyl. Neuropharmacology 1970 Nov; 9 (6): 539-51
23. von Cube B, Teschemacher H, Herz A, et al. Permeation of morphine-like acting substances to their sites of antinociceptive action in the brain after intravenous and intraventricular application and dependence upon lipid-solubility [in German]. Naunyn Schmiedebergs Arch Pharmakol 1970; 265 (5): 455-73
24. Chen SW, Maguire PA, Davies MF, et al. Evidence for mu1-opioid receptor involvement in fentanyl-mediated respiratory depression. Eur J Pharmacol 1996 Sep 26; 312 (2): 241-4
25. Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manage 1997 May; 13 (5): 254-61
26. Collett BJ. Opioid tolerance: the clinical perspective. Br J Anaesth 1998 Jul; 81 (1): 58-68
27. Miyazaki T, Hanaoka K, Namiki A, et al. Efficacy, safety and pharmacokinetic study of a novel fentanyl-containing matrix transdermal patch system in Japanese patients with cancer pain. Clin Drug Invest 2008 Apr; 28 (5): 313-25
28. Freynhagen R, von Giesen HJ, Busche P, et al. Switching from reservoir to matrix systems for the transdermal delivery of fentanyl: a prospective, multicenter pilot study in outpatients with chronic pain. J Pain Symptom Manage 2005 Sep; 30 (3): 289-97